{
    "2019-11-18": [
        [
            {
                "time": "2019-11-18",
                "original_text": "FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions",
                "features": {
                    "keywords": [
                        "FDA",
                        "Pfizer",
                        "Biosimilar",
                        "ABRILADA",
                        "approval",
                        "inflammatory conditions"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-11-18",
                "original_text": "Pfizer- A Stealth Blockbuster in Heart Drugs",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "blockbuster",
                        "heart drugs"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}